ABSTRACT
Introduction 954 Hodgkin lymphoma 955 Relapsed Hodgkin lymphoma 955 Refractory Hodgkin lymphoma 956 Prognostic factors after HDT and ASCT for Hodgkin 956
lymphoma Hodgkin lymphoma in first remission 957 Non-Hodgkin lymphoma 957 Relapsed diffuse large B cell lymphoma 957 Prognostic factors for relapsed DLBCL 958 Diffuse large B cell and other aggressive B cell lymphomas 958
in first remission Diffuse aggressive NHL which is ‘slow’ to enter remission 959 Follicular lymphoma in first remission 960 Relapsed follicular lymphoma 961
Mantle cell lymphoma 961 Burkitt lymphoma and atypical Burkitt lymphoma 962 Peripheral T cell lymphomas 962 Precursor T cell and B cell lymphoblastic leukemia/ 962
lymphoma Allogeneic stem cell transplantation in lymphomas 963 Graft-versus-tumor effects in lymphoma 963 Hodgkin lymphoma 963 Diffuse large B cell and other diffuse aggressive 963
non-Hodgkin lymphomas Indolent B cell non-Hodgkin lymphoma 964 Mantle cell lymphoma 964 Other aggressive non-Hodgkin lymphoma subtypes 964 Key points 964 References 965
High-dose therapy (HDT) and stem cell transplantation (SCT) has been in widespread use in the treatment of Hodgkin (HL) and non-Hodgkin lymphomas (NHLs) for more than 20 years. Despite this, the impact of this treatment on remission duration and overall survival for patients with these diseases remains poorly defined. High-dose therapy with autologous stem cell transplantation (ASCT) is now regarded as the standard of care for certain patients with relapsed and refractory HL or relapsed aggressive B cell NHL. This is supported by results from prospective, randomized clinical trials. The role of HDT and ASCT as a component of first-line therapy for certain ‘high risk’ patients with HL and NHL is also being better defined as results emerge from recently completed randomized studies.
